Biomedical papers - Ahead of Print

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | 10.5507/bp.2018.022

Mucosal delivery systems of antihypertensive drugs: A practical approach in general practice

Lukasz P. Bialya,b, Cezary Wojcikc, Izabela Mlynarczuk-Bialya,b
a Private General Practice (Praktyka Lekarska dr n. med. Lukasz Bialy), Warsaw, Poland
b Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland
c Department of Family Medicine, Oregon Health and Sciences University, Portland, OR, USA

Patients who are unable to receive oral medication (p.o.) are a major problem in outpatient settings, especially in home health care systems. Mucosal administration of drugs offers an alternative to the oral route, especially when the parenteral mode cannot be used. There are three main pathways of mucosal administration: sublingual/buccal, intranasal and rectal. We discuss the possibility of mucosal delivery of antihypertensive drugs. Perindopril arginine and Amlodipine besylate are registered in the EU as orodispersible tablets for oromucosal delivery, however, they are not available in all countries. For this reason, we describe other drugs suitable for mucosal delivery: Captopril and Nitrendipine in the sublingual system and Metoprolol tartrate, Propranolol and Furosemide by the transrectal route. Based on the published data and common clinical practice we discuss the use of mucosal delivery systems of all these antihypertensive drugs with special attention to their pharmacokinetics. We illustrate this mini-review with a case report of the prolonged-term use of mucosal delivery of sublingual Captopril and Nitrendipine combined with rectal Metoprolol tartrate and Furosemide in a patient with severe hypertension unable to receive medication p.o. This is also a report on the first human use of Furosemide-containing suppositories as well as prolonged-term transmucosal administration of these four drugs, describing a practical approach leading to successful control of severe hypertension with four antihypertensive drugs delivered via the mucosal route. The treatment was effective and without side effects; however, the long-term safety and efficacy of such therapy must be confirmed by randomized clinical trials.

Keywords: antihypertensive drugs, mucosal drug delivery, metoprolol, furosemide, suppositories

Received: October 26, 2017; Accepted: April 16, 2018; Prepublished online: May 15, 2018


References

  1. Mace AO, McLeod C, Yeoh DK, Vine J, Chen YP, Martin AC, Blyth CC, Bowen AC. Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational study. Arch Dis Child 2018;103(2):165-169. doi: 10.1136/archdischild-2017-313071 Go to original source... Go to PubMed...
  2. Sangeetha S, Nagasamy Venkatesh D, Krishan P, Saraswathi R. Mucosa as a route for systemic drug delivery. Res J Pharm Biol Chem Sci 2010;1(3):178-87.
  3. Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 2012;64(1):16-28. Go to PubMed...
  4. Sattar M, Sayed OM, Lane ME. Oral transmucosal drug delivery--current status and future prospects. Int J Pharm 2014;471(1-2):498-506. Go to PubMed...
  5. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002;41(9):661-80. Go to PubMed...
  6. Miro A, d'Angelo I, Nappi A, La Manna P, Biondi M, Mayol L, Musto P, Russo R, La Rotonda MI, Ungaro F, Quaglia F. Engineering poly(ethylene oxide) buccal films with cyclodextrin: a novel role for an old excipient? Int J Pharm 2013;452(1-2):283-91. Go to PubMed...
  7. Dey P, Maiti S. Orodispersible tablets: A new trend in drug delivery. J Nat Sci Biol Med 2010;1(1):2-5. Go to PubMed...
  8. Roy A. Orodispersible tablets: a review. Asian J Pharm Clin Res 2016;9:19-26.
  9. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004;21(6):433-76. Go to PubMed...
  10. FDA Guidelines https://www.fda.gov/downloads/Drugs/.../Guidances/ucm070578.pdf.
  11. Kaya A, Tatlisu MA, Kaplan Kaya T, Yildirimturk O, Gungor B, Karatas B, Yazici S, Keskin M, Avsar S, Murat A. Sublingual vs. Oral Captopril in Hypertensive Crisis. J Emerg Med 2016;50(1):108-15.
  12. Dave S, Shriyan D, Gujjar P. Newer drug delivery systems in anesthesia. J Anaesthesiol Clin Pharmacol 2017;33(2):157-63. Go to PubMed...
  13. Jagdale S, Shewale N, Kuchekar BS. Optimization of Thermoreversible In Situ Nasal Gel of Timolol Maleate. Scientifica (Cairo) 2016;2016:6401267. Go to PubMed...
  14. Jannin V, Lemagnen G, Gueroult P, Larrouture D, Tuleu C. Rectal route in the 21st Century to treat children. Adv Drug Deliv Rev 2014;73:34-49. Go to PubMed...
  15. Yuan Y, Cui Y, Zhang L, Zhu HP, Guo YS, Zhong B, Hu X, Zhang L, Wang XH, Chen L. Thermosensitive and mucoadhesive in situ gel based on poloxamer as new carrier for rectal administration of nimesulide. Int J Pharm 2012;430(1-2):114-9. Go to PubMed...
  16. Jug M, Hafner A, Lovric J, Kregar ML, Pepic I, Vanic Z, Cetina-Cizmek B, Filipovic-Grcic J. An overview of in vitro dissolution/release methods for novel mucosal drug delivery systems. J Pharm Biomed Anal 2018;147:350-366. doi: 10.1016/j.jpba.2017.06.072 Go to original source... Go to PubMed...
  17. Nair L, Bhargava HN. Comparison of in vitro dissolution and permeation of fluconazole from different suppository bases. Drug Dev Ind Pharm 1999;25(5):691-4. Go to PubMed...
  18. van Hoogdalem E, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet 1991;21(1):11-26. Go to PubMed...
  19. Srikrishna S, Cardozo L. The vagina as a route for drug delivery: a review. Int Urogynecol J 2013;24(4):537-43. Go to PubMed...
  20. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release 2005;103(2):301-13. Go to PubMed...
  21. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force M. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281-357. Go to PubMed...
  22. Remko M, Remková A. Perindopril arginin: nová sůl inhibitoru ACE perindoprilu a její přínos. Remedia 2007;17:421-4.
  23. Telejko E. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007;23(5):953-60. Go to PubMed...
  24. Brunton L, Chabner B, Knollmann B. Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2011.
  25. Fox KM, Investigators EUtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782-8. Go to PubMed...
  26. Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs 2006;6(5):327-34. Go to PubMed...
  27. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Investigators A. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906. Go to PubMed...
  28. Patel A, Group AC, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-40. Go to PubMed...
  29. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, Group HS. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358(18):1887-98. Go to PubMed...
  30. Václavík J. Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form. Vnitr Lek 2013;59(4):290-4. Go to PubMed...
  31. Summary of Product Characteristics https://www.drugs.com/uk/pdf/leaflet/571467.pdf.
  32. Glezer On Behalf Of The Optimum Program Participants MG. [Evaluation of Antihypertensive Efficacy and Patient Adherence to Treatment With the New Formulation Perindopril Arginine (Orally Disintegrating Tablet) in General Clinical Practice: OPTIMUM Program]. Kardiologiia 2016;56(4):36-41.
  33. Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet 1988;14(4):241-59. Go to PubMed...
  34. Eichelbaum M, Mikus G, Mast V, Fischer C, Kuhlmann U, Machleidt C. Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. J Cardiovasc Pharmacol 1988;12 Suppl 4:S6-10. Go to PubMed...
  35. Cherney D, Straus S. Management of Patients With Hypertensive Urgencies and Emergencies. J Gen Intern Med 2002;17:937-45. Go to PubMed...
  36. Kazerani H, Hajimoradi B, Amini A, Naseri MH, Moharamzad Y. Clinical efficacy of sublingual captopril in the treatment of hypertensive urgency. Singapore Med J 2009;50(4):400-2. Go to PubMed...
  37. Salkic S, Brkic S, Batic-Mujanovic O, Ljuca F, Karabasic A, Mustafic S. Emergency Room Treatment of Hypertensive Crises. Med Arch 2015;69(5):302-6. Go to PubMed...
  38. Karakilic E, Buyukcam F, Kocalar G, Gedik S, Atalar E. Same effect of sublingual and oral captopril in hypertensive crisis. Eur Rev Med Pharmacol Sci 2012;16(12):1642-5. Go to PubMed...
  39. Rohr G, Reimnitz P, Blanke P. Treatment of hypertensive emergency. Comparison of a new dosage form of the calcium antagonist nitrendipine with nifedipine capsules. Intensive Care Med 1994;20(4):268-71. Go to PubMed...
  40. Spah F, Grosser K. Treatment of hypertensive urgencies J Cardiovasc Pharmacol 1988;12:154-6. Go to PubMed...
  41. Park JW, Leithauser B, Jung F. Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. Clin Hemorheol Microcirc 2008;39(1-4):323-8. Go to PubMed...
  42. Dabrowski, Szwed. Higher efficacy of oral nitrendipine admininstration in comparison with sublingual route. Nadcisnienie Tetnicze 2005;9:168-77.
  43. Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992;80 Suppl 1:31-6. Go to PubMed...
  44. van Zwieten PA. Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. Clin Cardiol 1994;17(9 Suppl 3):III3-6. Go to PubMed...
  45. Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, Gargiulo P, Paolillo S, Petretta A, Chiariello M. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 2009;27(6):1136-51. Go to PubMed...
  46. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, group Vt. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31. Go to PubMed...
  47. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97. Go to PubMed...
  48. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, Investigators AT. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359(23):2417-28. Go to PubMed...
  49. Wright JT, Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney D, Hypertension Study G. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31. Go to PubMed...
  50. Sheraz MA, Ahsan SF, Khan MF, Ahmed S, Ahmad I. Formulations of Amlodipine: A Review. J Pharm (Cairo) 2016;2016:8961621. Go to PubMed...
  51. Mohanachandran PS, Krishna Mohan PR, Fels S, Bini KB, Beenu B, SHalina KK. Formulation and evaluation of mouth dispersible tablets of amlodipine besylate. Int J Appl Pharma 2010;2(3):1-6.
  52. Bhunia B, Varun j. Formulation and evaluation of orodispersible tablet of amlodipine besilate. International Journal Of Pharmacy&Technology 2011;3(4):3745-66.
  53. Product Characteristics http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con241806.pdf.
  54. Mascoli V, Kuruganti U, Bapuji A, Wang R, Damle B. Pharmacokinetics of a Novel Orodispersible Tablet of Amlodipine in Healthy Subjects. J Bioequiv Availab 2013;5:76-9.
  55. Liu Y, Jia J, Liu G, Li S, Lu C, Liu Y, Yu C. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Clin Ther 2009;31(4):777-83. Go to PubMed...
  56. Jang DJ, Bae SK, Oh E. Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients. Biomed Pharmacother 2014;68(8):1117-24. Go to PubMed...
  57. Uchida T, Yoshida M, Hazekawa M, Haraguchi T, Furuno H, Teraoka M, Ikezaki H. Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor. J Pharm Pharmacol 2013;65(9):1312-20. Go to PubMed...
  58. Blake CM, Kharasch ED, Schwab M, Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther 2013;94(3):394-9. Go to PubMed...
  59. Dollery C. Metoprolol Tartrate. New York: Churchill Livingston; 1999.
  60. Abou el Ela Ael S, Allam AA, Ibrahim EH. Pharmacokinetics and anti-hypertensive effect of metoprolol tartrate rectal delivery system. Drug Deliv 2016;23(1):69-78. Go to PubMed...
  61. de Stoppelaar FM, Stolk LM, Beysens AJ, Stappers JL, Gorgels AP. The relative bioavailability of metoprolol following oral and rectal administration to volunteers and patients. Pharm World Sci 1999;21(5):233-8. Go to PubMed...
  62. Shand DG. Pharmacokinetics of propranolol: a review. Postgrad Med J 1976;52 Suppl 4:22-5. Go to PubMed...
  63. Fitzgerald JD, O'Donnell SR. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol 1971;43(1):222-35. Go to PubMed...
  64. Barnwell SG, Laudanski T, Story MJ, Mallinson CB, Harris RJ, Cole SK, Keating M, Attwood D. Improved oral bioavailability of propranolol in healthy human volunteers using a liver bypass drug delivery system containing oleic acid. International Journal of Pharmaceutics 1992;88(1):423-32.
  65. Taylan B, Capan Y, Güven O, Kes S, Atilla Hincal A. Design and evaluation of sustained-release and buccal adhesive propranolol hydrochloride tablets. Journal of Controlled Release 1996;38(1):11-20.
  66. Ryu J-M, Chung S-J, Lee M-H, Kim C-K, Chang-Koo S. Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum. Journal of Controlled Release 1999;59(2):163-72. Go to PubMed...
  67. Sastri MS, Satyanarayana NV, Krishna DR, Diwan PV. In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. Arzneimittelforschung 1993;43(3):320-3. Go to PubMed...
  68. Sastry MSP, Satyanarayana NV, Diwan PV, Krishna DR. Formulation, Phafmacokinetic and Pharmacodynamic Evaluation of Fast Releasing Compressed Propranolol. HCL Suppositories. Drug Development and Industrial Pharmacy 1993;19(9):1089-96.
  69. Ogiso T, Iwaki M, Kashitani Y, Yamashita K. Enhancement effect of lauric acid on the rectal absorption of propranolol from suppository in rats. Chem Pharm Bull (Tokyo) 1991;39(10):2657-61. Go to PubMed...
  70. Cid E, Mella F, Lucchini L, Carcamo M, Monasterio J. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. Biopharm Drug Dispos 1986;7(6):559-66. Go to PubMed...
  71. de Leede LG, Hug CC, Jr., de Lange S, de Boer AG, Breimer DD. Rectal and intravenous propranolol infusion to steady state: kinetics and beta-receptor blockade. Clin Pharmacol Ther 1984;35(2):148-55. Go to PubMed...
  72. May CC, Oyler DR, Parli SE, Talley CL. Rectal propranolol controls paroxysmal sympathetic hyperactivity: a case report. Pharmacotherapy 2015;35(4):e27-31. Go to PubMed...
  73. Basappa VB, Sundaram D, Srinivasan B, Rajamanickam D, Varadharajan M. Design and Evaluation of Sustained Release Propranolol Hydrochloride Suppositories. Int J Pharm Sci Rev Res 2013;22(2):5-12.
  74. Chungi VS, Dittert LW, Smith RB. Gastrointestinal sites of furosemide absorption in rats. Int J Pharm 1979;4:27-38.
  75. Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol 1984;26(2):197-207. Go to PubMed...
  76. Prandota. Pharmacokinetics and metabolism of furosemide in man. European Journal of Drug Metabolism and Pharmacokinetics 1976;1:177-81.
  77. Kim EJ, Han KS, Lee MG. Gastrointestinal first-pass effect of furosemide in rats. J Pharm Pharmacol 2000;52(11):1337-43. Go to PubMed...
  78. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. Br J Clin Pharmacol 2007;64(6):804-9. Go to PubMed...
  79. Berko S, Regdon G, Jr., Ducza E, Falkay G, Eros I. In vitro and in vivo study in rats of rectal suppositories containing furosemide. Eur J Pharm Biopharm 2002;53(3):311-5. Go to PubMed...
  80. Regdon G, Fazekas T, Regdon G, Jr., Selmeczi B. Formulation and in vitro examination of furosemide containing suppositories and preliminary experiences of their clinical use. Pharmazie 1996;51(2):116-9. Go to PubMed...
  81. Regdon G, Fazekas T, Regdon G, Selmeczi B. [Formulation and in vitro examination of furosemide-containing suppositories and preliminary experiences of their clinical use]. Acta Pharm Hung 1997;67(1):19-23. Go to PubMed...
  82. Summary of product characteristics http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1510894262379.pdf.
  83. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 2002;17(12):937-45. Go to PubMed...